TScan Therapeutics, Inc. (TCRX)
|Net Income (ttm)||-26.13M|
|Trading Day||July 30|
|Day's Range||9.65 - 10.02|
|52-Week Range||9.38 - 12.32|
TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious ...
Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T ...
TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell...
TScan Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
TScan Therapeutics is a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system ... [Read more...]
|IPO Date |
Jul 16, 2021
|Stock Exchange |
|Ticker Symbol |